|Bid||0.7101 x 100|
|Ask||0.7170 x 100|
|Day's Range||0.6800 - 0.7200|
|52 Week Range||0.5200 - 3.3500|
|PE Ratio (TTM)||-1.00|
|Earnings Date||Aug 14, 2017 - Aug 18, 2017|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||4.00|
Along with its first quarter results, Durham’s Heat Biologics (HTBX) has outlined a new strategy focusing on combination therapies for the treatment of cancer – specifically, with checkpoint inhibitors or T cell co-stimulators – alone. The strategy comes at a time when the company has seen positive data from its ongoing Phase 2 trial of HS-110 for the treatment of lung cancer in combination with Bristol-Myers Squibb checkpoint inhibitor nivolumab,according to Heat CEO Jeff Wolf said Thursday. Heat Biologics plans to discontinue its other clinical program for the treatment of non-muscle invasive bladder cancer, along with additional preclinical programs, in order to focus those resources on combination programs, he says.
Heat to Double-Down on Checkpoint Combination Therapies Based on Positive Interim Data of HS-110+PD-1 Checkpoint in Lung Cancer; Acquires Pelican Therapeutics Which Brings with it a $15.2 Million CPRIT ...
Durham’s Heat Biologics (HTBX) has completed its acquisition of Austin, Texas-based immuno-oncology company Pelican Therapeutics, in a cash-and-stock deal valued at about $1.5 million . "We’ve been following Pelican and thinking about [the acquisition] for quite a while," said Heat CEO Jeff Wolf in an interview at the time of the deal’s announcement in March. "Pelican's two product candidates strengthen our portfolio in the emerging T cell activation space,” said Wolf in a statement, regarding the deal’s closing.